Celltrion is spotlighted

Published: 2011-04-27 06:57:00

Updated: 2011-04-27 06:57:00

Celltrion, the second largest KOSDAQ listed company, has been feted here in Korea, especially in the stock market as biosimilars are widely seen as a new engine of Korea’s economic growth. Samsung Group vowed to invest 500 billion won in it until 2014.

As the nation’s foremost biosimilar produ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK